The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.
October 18th 2024
Breelyn Wilky, MD, discusses updated efficacy and safety findings following treatment of botensilimab and balstilimab in refractory metastatic sarcoma.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Ripretinib Shows Antitumor Activity in Fourth-Line KIT/PDGFRA-Mutated Advanced GIST
November 23, 2020 - Ripretinib demonstrated clinically meaningful activity in patients with fourth-line or later advanced gastrointestinal stromal tumor and several, heterogeneous genetic subsets of KIT/PDGFRA mutations.
FDA Grants PTC596 Multiple Designations for Leiomyosarcoma, Glioma
November 18, 2020 - The FDA has granted a fast track designation and an orphan drug designation to the orally bioavailable small molecule tubulin-binding agent PTC596 for potential use in patients with leiomyosarcoma; the agent also received a rare pediatric disease designation and an orphan drug designation for potential use in patients with diffuse intrinsic pontine glioma.
Nivolumab/Ipilimumab Combo Is Effective, Safe in Advanced or Unresectable Angiosarcoma
November 13, 2020 - The combination of nivolumab and ipilimumab elicited an objective response rate of 25% and was found to be well tolerated in patients with advanced or unresectable angiosarcoma, according to cohort findings of the phase 2 DART trial.
JTCC and Georgetown’s Alliance in Cancer Research Achieves New Level With Immunotherapy Breakthrough
It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient.
Selinexor Significantly Improves PFS in Unresectable Dedifferentiated Liposarcoma
Single-agent selinexor resulted in a statistically significant prolongation of progression-free survival in patients with advanced unresectable dedifferentiated liposarcoma, meeting the primary end point of the phase 3 SEAL trial.
Fourth-Line Ripretinib Elicits Significant Responses in Advanced GIST
October 22nd 2020César Serrano-García, MD, PhD, highlights ripretinib and the meaningful benefit it provides as a fourth- and later-line therapy in patients with advanced gastrointestinal stromal tumor who harbor KIT or PDGFRA mutations.
Ripretinib Continues to Showcase Clinically Meaningful Benefit, Safety in Advanced GIST
October 19th 2020Ripretinib continues to show clinically meaningful benefit with an acceptable safety profile when used as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumor.